Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial.

What was studied

This randomized open-label trial compared adalimumab with subcutaneous infliximab. It was a head-to-head trial at several centers. People had axial spondyloarthritis. They also had past eye inflammation, called acute anterior uveitis (AAU). It had 28 people per group. Adalimumab was given every 2 weeks. Infliximab started by vein, then went under the skin. They were followed for 48 weeks. The main measure was an AAU flare.

What they found

1 AAU flare occurred in each group. The adjusted hazard ratio was 0.496, with a range of 0.025-9.768. Secondary measures did not differ significantly. They included vision, disease activity and function. Side events were similar in frequency and severity. No new safety signals were found.

What it means for patients

The authors say flare risk and other outcomes did not differ significantly. They say subcutaneous infliximab may be an alternative to adalimumab. It might help prevent flares and control disease.

Why it is not certain yet

The groups were small, with 28 people each. Few flares occurred. The range around the result was wide. The trial was open-label. Follow-up was 48 weeks.

Source

Comparison of the Risk of Acute Anterior Uveitis Flare Between Adalimumab and Subcutaneous Infliximab in Patients with Radiographic Axial Spondyloarthritis and Prior Acute Anterior Uveitis: A Randomized Controlled Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.